Linked Life Data

17237696

Source:http://linkedlifedata.com/resource/pubmed/id/17237696

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-1-22
pubmed:abstractText
Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways. It has been shown to prolong survival in patients with metastatic colorectal cancer. Cutaneous toxicity is relatively common because of the inhibition of EGFR of normal epidermal cells. We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy. His findings resolved within weeks of the discontinuation of the drug. Cicatricial ectropion is a potential sequela of EGFR inhibition by cetuximab and can resolve without surgical intervention with the discontinuation of this drug.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0740-9303
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
62-3
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:articleTitle
Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
pubmed:affiliation
Department of Oculoplastic and Reconstructive Surgery, Wilmer Eye Institute, Baltimore, Maryland 21287, USA. dgariba@jhmi.edu
pubmed:publicationType
Journal Article, Case Reports